Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: HighGain who wrote (1320)	1/28/1998 7:56:00 PM
From: Maxwell Fashola	Read Replies (1) \| Respond to of 2205

Highgain, It's called fear, and it is a stronger emotion than greed.

To: HighGain who wrote (1320)	1/29/1998 6:40:00 AM
From: John Curtis	Read Replies (1) \| Respond to of 2205

Highgain: Heavy selling perhaps equals shorts going at it? As for price decline after approval....welll....with biotech's approval is one thing, garnering market share, sales coming thru the door, etc., is another. Most people who speculate in bio-tech's are buying the "story," which, once approved typically gives them some immediate profit. A percentage of them aren't the types to stick around longer term and wait to see how the company develop's in its market sector. Just some thoughts.... John~

To: HighGain who wrote (1320)	1/31/1998 8:36:00 PM
From: needawin	Read Replies (1) \| Respond to of 2205

HighGain your post #1320 was right on the money ! ! If you wouldn't mind I would like to hear your opinion where atis goes from here short term. If I remember right when ubs got approval of their drug the stock went up then down short term. Later the stock did well. Another example when tmed got approval for their laser to treat prostrate cancer the stock surged from 4 to 16 and then melted down and is around 2 today. tmed's laser was ultimately not judged to be a better treatment than traditional methods. I'm not saying atis is akin to any of these stocks but if atis product is not perceived as better than conventional treatment or as an insufficient market size then whether true or not short term may see some more weekness in stock.